$CNTX
Context Therapeutics Inc. Stock $cntx

$cntx Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000184295222000029 Filed on March 23, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.633M	$174.7K	$930.7K
YoY Change	290.36%		-68.61%
% of Gross Profit
Research & Development	$3.805M	$590.0K	$1.642M
YoY Change	131.8%		-31.94%
% of Gross Profit
Depreciation & Amortization	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$3.805M	$769.5K	$1.642M
YoY Change	131.8%		-69.47%
Operating Profit	-$10.53M		-$2.572M
YoY Change	309.22%
Interest Expense	$64.24K	-$15.20K	$661.2K
YoY Change	-90.28%		-165.66%
% of Operating Profit
Other Income/Expense, Net	$123.9K		$0.00
YoY Change
Pretax Income	-$10.46M	-$784.8K	$6.644M
YoY Change	-257.38%		-204.08%
Income Tax	$0.00		$0.00
% Of Pretax Income			0.0%
Net Earnings	-$10.46M	-$784.8K	$6.644M
YoY Change	-257.38%		-204.08%
Net Earnings / Revenue
Basic Earnings Per Share	-$3.69		$3.07
Diluted Earnings Per Share	-$3.69	-$71.60K	-$3.96
COMMON SHARES
Basic Shares Outstanding	2.834M shares		348.4K shares
Diluted Shares Outstanding	2.834M shares		2.055M shares

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$49.64M		$341.0K
YoY Change	14454.07%		50.5%
Cash & Equivalents	$49.64M	$290.7K	$341.0K
Short-Term Investments
Other Short-Term Assets	$1.620M		$8.670K
YoY Change	18586.97%		-33.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$51.26M	$299.3K	$349.7K
YoY Change	14556.53%		45.95%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.39K		$117.6K
YoY Change	-57.16%		246.58%
Total Long-Term Assets	$50.39K	$168.0K	$117.6K
YoY Change	-57.16%		246.58%
TOTAL ASSETS
Total Short-Term Assets	$51.26M	$299.3K	$349.7K
Total Long-Term Assets	$50.39K	$168.0K	$117.6K
Total Assets	$51.31M	$467.3K	$467.3K
YoY Change	10878.25%		70.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.826M	$2.708M	$2.708M
YoY Change	-32.56%		30.95%
Accrued Expenses	$1.207M	$956.0K	$956.0K
YoY Change	26.27%		384.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00		$5.829M
YoY Change	-100.0%		-73.31%
Long-Term Debt Due	$0.00		$55.01K
YoY Change	-100.0%
Total Short-Term Liabilities	$3.033M	$9.548M	$9.548M
YoY Change	-68.23%		-60.39%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00		$69.04K
YoY Change	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00		$69.04K
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.033M	$9.548M	$9.548M
Total Long-Term Liabilities	$0.00		$69.04K
Total Liabilities	$3.033M	$9.617M	$9.617M
YoY Change	-68.46%		-60.11%
SHAREHOLDERS EQUITY
Retained Earnings		-$18.80M
YoY Change
Common Stock		$332.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$48.27M	-$16.92M	-$9.150M
YoY Change
Total Liabilities & Shareholders Equity	$51.31M	$467.3K	$467.3K
YoY Change	10878.25%		70.84%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	-$10.46M	-$784.8K	$6.644M
YoY Change	-257.38%		-204.08%
Depreciation, Depletion And Amortization	$0.00
YoY Change
Cash From Operating Activities	-$8.799M	-$176.0K	-$1.035M
YoY Change	750.5%		-63.52%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$250.0K
YoY Change
Cash From Investing Activities	-$250.0K		$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$58.39M	350.0K	$1.149M
YoY Change	4981.92%		-41.3%
NET CHANGE
Cash From Operating Activities	-$8.799M	-176.0K	-$1.035M
Cash From Investing Activities	-$250.0K		$0.00
Cash From Financing Activities	$58.39M	350.0K	$1.149M
Net Change In Cash	$49.34M	174.0K	$114.4K
YoY Change	43020.53%		-113.02%
FREE CASH FLOW
Cash From Operating Activities	-$8.799M	-$176.0K	-$1.035M
Capital Expenditures	$0.00
Free Cash Flow	-$8.799M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001842952
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q2	dei	Entity Public Float EntityPublicFloat	0	USD
CY2021Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1667
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Auditor Name AuditorName	CohnReznick LLP
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-04321
CY2021	dei	Entity Registrant Name EntityRegistrantName	CONTEXT THERAPEUTICS INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3738787
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	2001 Market Street
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 3915
CY2021	dei	Entity Address Address Line3 EntityAddressAddressLine3	Unit #15
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Philadelphia
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19103
CY2021	dei	City Area Code CityAreaCode	267
CY2021	dei	Local Phone Number LocalPhoneNumber	225-7416
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	CNTX
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15966053	shares
CY2021	dei	Auditor Firm AuditorFirmId	596
CY2021	dei	Auditor Location AuditorLocation	Holmdel, New Jersey
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49635197	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	290670	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1620164	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8672	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	51255361	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	299342	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	50389	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	50367	USD
CY2021Q4	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2020Q4	us-gaap	Deferred Costs DeferredCosts	117631	USD
CY2021Q4	us-gaap	Assets Assets	51305750	USD
CY2020Q4	us-gaap	Assets Assets	467340	USD
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2020Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5829292	USD
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	55014	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1826294	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2707861	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1207121	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	955989	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3033415	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9548156	USD
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	69040	USD
CY2021Q4	us-gaap	Liabilities Liabilities	3033415	USD
CY2020Q4	us-gaap	Liabilities Liabilities	9617196	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	7771223	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15966053	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15966053	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	331789	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	331789	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	15966	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	332	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	77510809	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1876159	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29254440	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18797570	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48272335	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-16921079	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51305750	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	467340	USD
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	3087832	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3805067	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1641501	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3632920	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	930667	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	6644465	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.69
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-10525819	USD
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2054875	shares
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-2572168	USD
CY2021	us-gaap	Interest Expense InterestExpense	64240	USD
CY2020	us-gaap	Interest Expense InterestExpense	661224	USD
CY2021	cntx	Fair Value Adjustment On Convertible Debt FairValueAdjustmentOnConvertibleDebt	9317	USD
CY2020	cntx	Fair Value Adjustment On Convertible Debt FairValueAdjustmentOnConvertibleDebt	9877857	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	123872	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10456870	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.07
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.69
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.96
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2833674	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	348368	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2833674	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-23960756	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	219245	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	-97000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	6644465	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-16921079	USD
CY2021	cntx	Temporary Equity Offering Costs TemporaryEquityOfferingCosts	310021	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	137497	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	53330	USD
CY2021	cntx	Stock Issued During Period Value Conversion Of Preferred Shares And Redeemable Common Shares StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares	21064623	USD
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	511079	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10456870	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48272335	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10456870	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	6644465	USD
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	3087832	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	371895	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	511079	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	219245	USD
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	46315	USD
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	661224	USD
CY2021	cntx	Fair Value Adjustment On Convertible Debt FairValueAdjustmentOnConvertibleDebt	9317	USD
CY2020	cntx	Fair Value Adjustment On Convertible Debt FairValueAdjustmentOnConvertibleDebt	9877857	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	125577	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1611492	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4332	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-866007	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	556270	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	252655	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	757701	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8799487	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1034620	USD
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	250000	USD
CY2020	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-250000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	25000	USD
CY2021	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	124054	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	24428626	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	28982575	USD
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	58394036	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1149054	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	49344549	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	114434	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	341037	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	226603	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49685586	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	341037	USD
CY2021	cntx	Warrants Issued WarrantsIssued	309390	USD
CY2020	cntx	Warrants Issued WarrantsIssued	78967	USD
CY2021	us-gaap	Stock Issued1 StockIssued1	2837832	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2021	cntx	Deferred Offering Cost Incurred But Not Yet Paid DeferredOfferingCostIncurredButNotYetPaid	102071	USD
CY2020	cntx	Deferred Offering Cost Incurred But Not Yet Paid DeferredOfferingCostIncurredButNotYetPaid	117631	USD
CY2021	cntx	Increase Decrease In Fair Value Of Redeemable Common Stock To Redemption Value IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue	53330	USD
CY2020	cntx	Increase Decrease In Fair Value Of Redeemable Common Stock To Redemption Value IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue	97000	USD
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	21064623	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business Context Therapeutics Inc. (the “Company”) is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The Company was organized in April 2015 under the laws of the State of Delaware. The Company’s operations are located in Philadelphia, Pennsylvania. In April 2021, the Company completed a reverse triangular merger, which resulted in Context Therapeutics Inc. becoming the sole holder of 100% of the membership interests in Context Therapeutics LLC. In connection with the merger, all common units, preferred units, options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converted into common stock, preferred stock, options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. As this was a transaction between entities under common control, the carryover basis of accounting was used to record the assets, liabilities and equity of Context Therapeutics LLC. Further, as a common control transaction, the consolidated financial statements of the Company reflect the merger transaction as if it had occurred as of the earliest period presented herein.
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29300000	USD
CY2021Q4	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	4853533	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	480415	shares
CY2021Q4	cntx	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	9816	shares
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	24400000	USD
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Reclassification of Prior Year PresentationCertain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	50389	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </span></div>Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the fair value of common stock, share-based compensation arrangements, the fair value of warrants, the fair value of convertible debt, and prepayments, accruals and associated expense related to research and development activities performed for the Company by third parties.
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10456870	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	50000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49635197	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	290670	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	50367	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49685586	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	341037	USD
CY2020Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	100000	USD
CY2021Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	0	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	184983	shares
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	3100000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.69
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6006691	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	6644465	USD
CY2021	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	USD
CY2020	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	5573558	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10456870	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1070907	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2833674	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	348368	shares
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.07
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10456870	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	6644465	USD
CY2021	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	0	USD
CY2020	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	5573558	USD
CY2021	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2020	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-9216633	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10456870	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8145726	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2833674	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	348368	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1706507	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2833674	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2054875	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.69
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.96
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1207121	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	436990	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	0	USD
CY2021Q4	cntx	Clinical Trial Liabilities Current ClinicalTrialLiabilitiesCurrent	339072	USD
CY2020Q4	cntx	Clinical Trial Liabilities Current ClinicalTrialLiabilitiesCurrent	126173	USD
CY2021Q4	cntx	Manufacturing Development Liabilities Current ManufacturingDevelopmentLiabilitiesCurrent	0	USD
CY2020Q4	cntx	Manufacturing Development Liabilities Current ManufacturingDevelopmentLiabilitiesCurrent	560000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	345530	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	0	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	85529	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	269816	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	955989	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	100000	USD
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	24400000	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5500000	shares
CY2021Q2	cntx	Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized As A Percentage Of Outstanding Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock	0.04
CY2020	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	7512	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	130059	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	130059	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.30
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10414	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.67
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	14416	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.79
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24830	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.84
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	481861	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.05
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	506691	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.68
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M18D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	506691	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.68
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y3M18D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.84
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.34
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1500000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	421880	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	326551	USD
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	10000	USD
CY2020	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	10000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4983415	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4983415	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3199412	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	421880	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	249874	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	249874	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	43526	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	147659	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5802828	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3569489	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	527181	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	0	USD
CY2021Q4	cntx	Net Deferred Tax Asset Liabilities Gross NetDeferredTaxAssetLiabilitiesGross	5275647	USD
CY2020Q4	cntx	Net Deferred Tax Asset Liabilities Gross NetDeferredTaxAssetLiabilitiesGross	3569489	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5275647	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5275647	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3569489	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1700000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	200000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.025
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.118
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0.075
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0.255
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.092
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.009
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.163
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.031
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD

Files In Submission

Name	View Source	Status
0001842952-22-000029-index-headers.html	Edgar Link	pending
0001842952-22-000029-index.html	Edgar Link	pending
0001842952-22-000029.txt	Edgar Link	pending
0001842952-22-000029-xbrl.zip	Edgar Link	pending
amendment1tosahmoud-oncost.htm	Edgar Link	pending
cntx-20211231.htm	Edgar Link	pending
cntx-20211231.xsd	Edgar Link	pending
cntx-20211231_cal.xml	Edgar Link	unprocessable
cntx-20211231_def.xml	Edgar Link	unprocessable
cntx-20211231_g1.jpg	Edgar Link	pending
cntx-20211231_g10.jpg	Edgar Link	pending
cntx-20211231_g11.jpg	Edgar Link	pending
cntx-20211231_g12.jpg	Edgar Link	pending
cntx-20211231_g13.jpg	Edgar Link	pending
cntx-20211231_g14.jpg	Edgar Link	pending
cntx-20211231_g15.jpg	Edgar Link	pending
cntx-20211231_g16.jpg	Edgar Link	pending
cntx-20211231_g17.jpg	Edgar Link	pending
cntx-20211231_g18.jpg	Edgar Link	pending
cntx-20211231_g19.jpg	Edgar Link	pending
cntx-20211231_g2.jpg	Edgar Link	pending
cntx-20211231_g3.jpg	Edgar Link	pending
cntx-20211231_g4.jpg	Edgar Link	pending
cntx-20211231_g5.jpg	Edgar Link	pending
cntx-20211231_g6.jpg	Edgar Link	pending
cntx-20211231_g7.jpg	Edgar Link	pending
cntx-20211231_g8.jpg	Edgar Link	pending
cntx-20211231_g9.jpg	Edgar Link	pending
cntx-20211231_htm.xml	Edgar Link	completed
cntx-20211231_lab.xml	Edgar Link	unprocessable
cntx-20211231_pre.xml	Edgar Link	unprocessable
contexttherapeuticsex311ce.htm	Edgar Link	pending
contexttherapeuticsex312ce.htm	Edgar Link	pending
contexttherapeuticsex321ce.htm	Edgar Link	pending
exhibit231cohnreznickconse.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
levitemploymentagreement10.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNTX
Context Therapeutics Inc. Stock $cntx

2021 Form 10-K Financial Statement

#000184295222000029 Filed on March 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNTX Context Therapeutics Inc. Stock $cntx

2021 Form 10-K Financial Statement

#000184295222000029 Filed on March 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNTX
Context Therapeutics Inc. Stock $cntx